FDA request delays Sarepta's Duchenne drug

FDA has asked Sarepta Therapeutics for more data on its Duchenne muscular dystrophydrug, eteplirsen, according to CNBC. The regulator's request could push the drug's filing to mid-2015, rather than its originally planned date of the end of this year. FDA has requested results of up to 168 weeks from a mid-stage trial. The company reported data from up to 144 weeks in July.